Broad-spectrum drugs, on the other hand, could limit the spread of a pathogen at an early stage and save many lives. While ...
NanoViricides, Inc. (NYSE American: NNVC) presented its latest advancements at the MicroCap <a target=_blank href= ...
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
In addition, antivirals are often only effective against a narrow spectrum of viruses. To better combat future viral pandemics, it is essential to have drugs with broad antiviral activity that can ...
(MENAFN- Investor Brand Network) NanoViricides, Inc. (NYSE American: NNVC) announced significant progress on NV-387, a broad-spectrum antiviral demonstrating superior efficacy in animal models ...
Multi-Modal Models: A multi-modal discovery approach was implemented that engineered-in potency against the novel target and engineered-out a specific off-target interaction. The NCE library displayed ...
In this scenario, NV-387 stands apart in the field of antiviral countermeasures in ... and (ii) the activity spectrum of NV-387 is so broad, encompassing not just a type of virus, but across ...
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as ...